Cited by 665Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Open access

Stein, Evan A., Mellis, Scott, Yancopoulos, George D., Stahl, Neil, Logan, Douglas, Smith, William B., Lisbon, Eleanor, Gutierrez, Maria, Webb, Cheryle, Wu, Richard, Du, Yunling, Kranz, Therese, Gasparino, Evelyn, Swergold, Gary D.·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1105803

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS: In healthy volunteers, we performed two randomized, single ascending-dose studies of REGN727 administered either intravenously (40 subjects) or subcutaneously (32 subjects), as compared with placebo. These studies were followed by a randomized, placebo-controlled, multiple-dose trial in adults with heterozygous familial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hypercholesterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >100 mg per deciliter [2.6 mmol per liter]) or a modified diet alone (10 subjects) (baseline LDL cholesterol, >130 mg per deciliter [3.4 mmol per liter]). REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43. The primary outcome for all studies was the occurrence of adverse events. The principal secondary outcome was the effect of REGN727 on the lipid profile. RESULTS: Among subjects receiving REGN727, there were no discontinuations because of adverse events. REGN727 significantly lowered LDL cholesterol levels in all the studies. In the multiple-dose study, REGN727 doses of 50, 100, and 150 mg reduced measured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per deciliter (2.00 mmol per liter), 61.3 mg per deciliter (1.59 mmol per liter), and 53.8 mg per deciliter (1.39 mmol per liter), for a difference in the change from baseline of -39.2, -53.7, and -61.0 percentage points, respectively, as compared with placebo (P<0.001 for all comparisons). CONCLUSIONS: In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01026597, NCT01074372, and NCT01161082.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1105803

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371

Show all 15 references

Research works printed but not linked: 1

Olsson AG, 2001, Clin Cardiol, 24, III

Sorted by citations

Items 501–600 of 665

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study
Shi, J., Li, X., Zhang, W., Niu, Y., Lin, N., Zhang, H., Ning, G., Fan, J., Qin, L., Su, Q., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.664583 · Cited by 4
Genetic stratification for primary prevention of coronary artery disease
Roberts, R., & Campillo, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000542 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Genetic risk and its role in primary prevention of CAD
Roberts, R., Chavira, J., & Venner, E. (2022) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2022.07 · Cited by 4
Novel pharmacotherapies of familial hyperlipidemia
Drakopoulou, M. I., Toutouzas, K. P., & Stefanadis, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.012 · Cited by 4
PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang, E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.263 · Cited by 4
PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Morales-Villegas, E. (2014) · Current Hypertension Reviews · doi:10.2174/1573402110666140702092415 · Cited by 4
PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Rashid, H. N. Z., Meredith, I. T., & Nasis, A. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.12.005 · Cited by 4
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices
Wang, E. Q., Plotka, A., Salageanu, J., Baltrukonis, D. J., Mridha, K., Frederich, R. C., & Sullivan, B. E. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.454 · Cited by 4
Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
Turgeon, R. D., & Pearson, G. J. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170707 · Cited by 5
Naturally Occurring PCSK9 Inhibitors: An Updated Review
Huh, J., & Kim, H. W. (2025) · Molecules · doi:10.3390/molecules30173582 · Cited by 3
Evolocumab Treatment in Dyslipidemic Patients Undergoing Coronary Artery Bypass Grafting: One-Year Safety and Efficacy Results
Nasso, G., Vignaroli, W., Amodeo, V., Bartolomucci, F., Larosa, C., Contegiacomo, G., Demola, M. A., Girasoli, C., Valenzano, A., Fiore, F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102987 · Cited by 4
Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?
Hochholzer, W., & Giugliano, R. P. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0290-8 · Cited by 3
Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Siemelink, M. A., van der Laan, S. W., Timmers, L., Hoefer, I. E., & Pasterkamp, G. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990371 · Cited by 3
The limitations of opportunistic epidemiology, pseudopod epidemiology
Kuller, L. H. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0196-9 · Cited by 3
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Yang, S., & Moon, Y.-A. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0353-5 · Cited by 3
A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
Alali, R. A. (2019) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2019.01.31812 · Cited by 3
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups
Wu, N., Li, Z.-F., Lu, M.-Y., & Li, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2321374 · Cited by 3
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
Basak, A. (2025) · Biomolecules · doi:10.3390/biom15040468 · Cited by 3
Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
Suh, S., Jung, C. H., Hong, S. J., Kim, J., & Choi, S. H. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.2.77 · Cited by 3
LDL-cholesterol reduction in chronic kidney disease: options beyond statins
Goonasekera, M. A., Mafham, M. M., & Haynes, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000628 · Cited by 3
Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk
Phan, B. A. P., & Toth, P. P. (2013) · Clinical Lipidology · doi:10.2217/clp.13.9 · Cited by 3
Revascularization Versus Medical Treatments in Stable Coronary Artery Disease
Risos, L., & Berkenboom, G. M. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000051 · Cited by 3
Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?
Grundy, S. M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0305-7 · Cited by 3
Exploring Predisposition and Treatment Response—the Promise of Genomics
Pan, S., & Knowles, J. W. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2012.04.006 · Cited by 3
Biologics for the Treatment of Dyslipidemias
Yoon, C. H., & Watson, K. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013511425 · Cited by 3
Einführung der PCSK9-Inhibitoren
Klose, G. (2016) · Herz · doi:10.1007/s00059-016-4428-2 · Cited by 3
PCSK9 inhibition: A promise fulfilled?
Solaru, K. W., Mohan, C., & Rocco, M. B. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83.s2.05 · Cited by 3
Update in Cardiology: Vascular Risk and Cardiac Rehabilitation
Galve, E., Castro, A., Cordero, A., Dalmau, R., Fácila, L., García-Romero, A., Mazón, P., Sanmartín, M., & Garcia, A. A. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.10.007 · Cited by 3
Lipoprotein(a)
Koschinsky, M. L., Boffa, M. B., & Marcovina, S. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00010-4 · Cited by 3
Genetic considerations in the treatment of familial hypercholesterolemia
Moyer, A. M., & Baudhuin, L. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.33 · Cited by 3
Atherosclerosis Risk Factors
Haverich, A., & Boyle, E. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-20245-3_2 · Cited by 4
The genomic basis of medicine
Stankiewicz, P., & Lupski, J. R. (2020) · doi:10.1093/med/9780198746690.003.0030 · Cited by 3
Proprotein Convertases
Szanto, A. J. P. K., & Bassi, D. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_10038 · Cited by 3
How to verify the analytical and clinical performance of ELISA immunoanalysis in the real laboratory practice. PCSK9 as an example
Vacková, T., Jabor, A., Kubíček, Z., & Franeková, J. (2024) · Journal of Immunological Methods · doi:10.1016/j.jim.2024.113693 · Cited by 2
Novel drug design and repurposing: An opportunity to improve translational research in cardiovascular diseases?
Rodríguez‐Zavala, J. S., & Zazueta, C. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400492 · Cited by 2
A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes
Zhong, X., Wei, Q., Tiwari, A., Wang, Q., Tan, Y., Chen, R., Yan, Y., Cox, N. J., & Bingshan, L. (2026) · npj Drug Discovery. · doi:10.1038/s44386-025-00032-3 · Cited by 3
PCSK9 inhibitors: an updated patent review 2024–2025
Fassi, E. M. A., Albani, M., d’Adduzio, L., Milano, E. G., Lammi, C., & Grazioso, G. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2674748 · Cited by 2
Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9 ‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials
Zayed, J. A., Al‐Awamleh, N. A., Hamad, M., Hdaib, M. I. M., & Ayesh, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70944 · Cited by 2
Benchmarking Bayesian Colocalization Methods in Validating Mendelian Randomization-identified Targets
Zhang, W., Yoshiji, S., SLADEK, R. M., Dupuis, J., & Lu, T. (2026) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzag087 · Cited by 2
Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents
Kohli, P., & Giugliano, R. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413480270 · Cited by 2
The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol
Blom, D. J., Marais, A. D., Raal, F. J., & Lambert, G. C. (2013) · Clinical Lipidology · doi:10.2217/clp.13.1 · Cited by 2
SLC30A8: A Complex Road from Association to Function
Flannick, J. A., & Lowe, W. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_18 · Cited by 2
Pharmacokinetics and Pharmacodynamics of Alirocumab, and Effects on PCSK9 and Low-Density Lipoprotein Cholesterol, in Japanese and Non-Japanese Patients
Hurbin, F., Lü, Q., Baccara‐Dinet, M. T., Takagi, Y., Shitara, Y., HORIUCHI, S., DiCioccio, A. T., Kobayashi, M., & Brunet, A. (2019) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.50.73 · Cited by 2
Exome-wide screening identifies novel rare risk variants for bone mineral density
He, D., Pan, C., Zhao, Y., Wei, W., Qin, X., Cai, Q., Shi, S.-Q., Chu, X., Zhang, N., Jia, Y., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06710-0 · Cited by 3
The interplay of LDLR, PCSK9, and lncRNA- LASER genes expression in coronary artery disease: Implications for therapeutic interventions
Ghiasvand, T., Karimi, J., Khodadadi, I., Yazdi, A., Khazaei, S., Kichi, Z. A., & Hosseini, S. K. (2025) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2025.106969 · Cited by 2
Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review
Јаnkovic, S., Tešić, D., Anđelković, J., & Kostić, M. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1501679 · Cited by 2
Mecanismos fisiopatologicos de la dislipidemia
Fernández, C. I. J., Bravo, J. I., Urbina, F. D., Blanco, J. K., & Zumaran, B. A. (2023) · Nova · doi:10.22490/24629448.6882 · Cited by 2
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727
Salam, A. M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.707193 · Cited by 2
Established and Emerging Approaches for the Management of Dyslipidaemia
Norata, G. D. (2012) · Scientifica · doi:10.6064/2012/482423 · Cited by 2
What do we know about lipoprotein(a)?
Cybulska, B., & Kłosiewicz−Latoszek, L. (2015) · Kardiologia Polska · doi:10.5603/kp.a2014.0244 · Cited by 2
Postępowanie w heterozygotycznej hipercholesterolemii rodzinnej. Stanowisko Forum Ekspertów Lipidowych
Rynkiewicz, A., Cybulska, B., Banach, M., Filipiak, K. J., Guzik, T. J., Idzior−Waluś, B., Imiela, J., Jankowski, P., Kłosiewicz−Latoszek, L., Limon, J., et al. (2013) · Family Medicine & Primary Care Review · Cited by 2
Update on PCSK9 therapies for the treatment of dyslipidemia
Singh, A., & Davidson, M. H. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1131120 · Cited by 2
Genetics of Coronary Disease
Kral, B. G., & Becker, L. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00008-5 · Cited by 3
In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors
Salowe, S. P., Zhang, L., Zokian, H. J., Gesell, J. J., Zink, D. L., Wiltsie, J., Ai, X., Kavana, M., & Pinto, S. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116657312 · Cited by 2
Review on PCSK9: A Pertinent Therapeutic Target in Cardiovascular Disease
Singh, S. K., & Jha, M. K. (2023) · Current Bioactive Compounds · doi:10.2174/0115734072270060230921093431 · Cited by 1
Target‐Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data
Kovalenko, P., Harnisch, L. O., Mendell, J., Wang, Y., Davis, J. D., & DiCioccio, A. T. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1523 · Cited by 1
Beyond CCR5 and HLA: rare genetic variants in HIV acquisition and disease progression
Amujal, M., Mukisa, J., Katagirya, E., Kyobe, S., Diphoko, T., Mwesigwa, S., Sebetso, G., Mboowa, G., Jjingo, D., Kateete, D. P., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1874407 · Cited by 1
Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
Huang, S.-J., Huang, P. H., Song, N.-N., Jia, X.-H., Gao, H., Lu, Z., & Wen, X. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105003 · Cited by 1
Therapeutic Options: Lifestyle Measures and Pharmacological Approaches
Wilkinson, I. B., & King, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-14556-3_29 · Cited by 1
Do animal models of vein graft atherosclerosis predict outcomes in man?
Yazdani, S. K., Otsuka, F., Nakano, M., Finn, A. V., & Virmani, R. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.028 · Cited by 1
Neue Medikamente in der Kardiologie
Czepluch, F. S., Hasenfuss, G. P., & Jacobshagen, C. (2014) · Der Internist · doi:10.1007/s00108-013-3418-1 · Cited by 1
PCSK9 : une nouvelle cible pour le traitement de l’hypercholestérolémie
Cariou, B. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70530-3 · Cited by 1
The Newest Frontier in Cholesterol Management; PSCK 9
Dashwood, A. M. (2014) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000127 · Cited by 1
Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors
Manolis, A. S., Manolis, T. A., & Melita, H. (2013) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v9i1.578 · Cited by 1
MIPOMERSEN: A NOVEL THERAPEUTIC DRUG FOR THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA, HYPERLIPIDAEMIA, AND HYPERCHOLESTEROLEMIA
Kumar, A., Acharya, A., Nandi, D., Sharma, N., & Chitkara, E. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 1
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition—The Dream of Translational Medicine
Uppugunduri, C. R. S., & George, M. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000324 · Cited by 1
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
Anders, H., Rovin, B. H., Jayne, D. R. W., Brunetta, P. G., Coppo, R., Davidson, A., Devarapu, S. K., de Zeeuw, D., Duffield, J. S., Eulberg, D., et al. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.06.009 · Cited by 1
Production of large, defined genome modifications in rats by targeting rat embryonic stem cells
Lee, J. D., Wang, J., Ally, R., Trzaska, S., Hickey, J., Mujica, A., Miloscio, L., Mastaitis, J. W., Morse, B., Smith, J., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.11.012 · Cited by 1
Serum PCSK9 levels in infants with deviant birth weight: a biomarker of the lipoprotein metabolism
Vlahos, A. P., Rallis, D., Lianou, A., Baltogianni, M. S., Dermitzaki, N., Maragoudaki, E., Papastergiou, E., Tzallas, C. S., Tsabouri, S., Makis, A. C., et al. (2023) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2023.2188108 · Cited by 1
Genetics of Coronary Artery Disease in Diabetes Mellitus
Morieri, M. L., & Doria, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_6 · Cited by 1
Familial hypercholesterolemia with special focus on Japan
Kobayashi, J., Minamizuka, T., Tada, H., & Yokote, K. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117847 · Cited by 1
Whole exome sequencing analyses reveal novel genes in telomere length and their biomedical implications
Liu, W., Wu, B., Liu, Y., Chen, S.-D., Zhang, Y.-R., Deng, Y., Wu, X., He, X., Yang, J., Feng, J., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01203-2 · Cited by 2
Knowledge of PCSK9 and Continued Educational Gaps
Larkin, A. T., HEALY, C. S., & Toth, P. P. (2015) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000036 · Cited by 1
Update on PCSK9 Inhibitors and New Therapies
Stein, E. A., & Raal, F. J. (2016) · US Endocrinology · doi:10.17925/use.2016.12.01.18 · Cited by 1
Self-citation
Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber
Corral, P., & Ruiz, Á. J. (2017) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2017.06.001 · Cited by 1
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
Kostapanos, M. S., Cacciottolo, P. J., Hubsch, A., Pavey, H., Hurlock, J., Maki-Petaja, K. M., Wilkinson, I. B., & Cheriyan, J. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1677673 · Cited by 1
PCSK9 Monoclonal Antibody: 12 Years, from Basic Research to Clinical Application
应, 航. (2019) · Advances in Clinical Medicine · doi:10.12677/acm.2019.911194 · Cited by 1
Pediatric Preventive Cardiology
Ward, K. M., Greco, M. M., Peterson, A. L. H., Matossian, D., & Benuck, I. (2024) · Springer eBooks · doi:10.1007/978-3-031-07563-6_107 · Cited by 1
PCSK9 in South African Variants of Familial Hypercholesterolemia
Getz, G. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.059 · Cited by 1
The Genetic and Proteomic Detereminants of the Risk of Coronary Artery Disease
Almontashiri, N. A. M. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-6541 · Cited by 1
Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition
Das, G. C., & Rees, A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000049 · Cited by 1
Genome-wide scan and fine-mapping of rare nonsynonymous associations implicates intracellular lipolysis genes in fat distribution and cardio-metabolic riskPreprint
Lotta, L. A., Dong, L., Li, C., Patel, S., Stewart, I. D., Lim, K., Day, F. R., Wheeler, E., Glastonbury, C. A., de Streek, M. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372128 · Cited by 2
Valuable lessons from analyses of common signs and symptoms in rare diseases
Matsumoto, K. (2021) · Allergology International · doi:10.1016/j.alit.2021.08.011 · Cited by 1
Editorial commentary: Genetics keeps on giving: A possible vaccine for heart disease
Roberts, R. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.02.008 · Cited by 1
Development of Inhibitors of Human PCSK9 as Potential Regulators of LDL-Receptor and Cholesterol
Alghamdi, R. H. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-5631 · Cited by 1
Pharmacometrics of Hyperlipidemia
Emery, M. G., Haughney, P. C., & Gibbs, J. P. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1304-6_19
Antibodies in Phase III Studies for Immunological Disorders
Ward, P., & Bodmer, M. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch29
Challenges and opportunities in pharmacogenomics : studies in cardiovascular disease and asthma
Leusink, M. (2015) · Utrecht University Repository (Utrecht University)
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Little, P. J., Chait, A., Januszewski, A. S., Bobik, A., O'Neal, D. N., & Jenkins, A. J. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_23
Lipid Lowering Drugs
Iqbal, O., Syed, D., & Fareed, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_220
New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes
Singh, R., Hristová, K., Fedačko, J., Elkilany, G. N., & Verma, N. (2015) · Journal of Cardiology and Therapy · doi:10.17554/j.issn.2309-6861.2015.02.93
New Treatment Approaches for Dyslipidemia and its Management
Vorsanger, M., & Underberg, J. A. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0333-x
The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia
Pokharel, Y., Virani, S. S., & Ballantyne, C. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0508-7
Hopes soar as cholesterol plummets with new drug class
Holmes, D. I. R. (2012) · Nature Medicine · doi:10.1038/nm0512-633
Monoclonal antibody therapy lowers LDL-cholesterol levels
Carney, E. F. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.55
Antikörper bei Hypercholesterinämie?
Brunn, D., Kuhn, B. R., Schaub, V., Sitzler, R., Zündorf, I., & Dingermann, T. (2012) · Pharmazie in unserer Zeit · doi:10.1002/pauz.201290083
Secondary Prevention of Heart Disease in Women: Gaps in Care/Gaps in Knowledge—Where Do We Need to Focus Our Attention
Lau, E. S., & Foody, J. M. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0452-7
Nuevos fármacos para el tratamiento de la hipercolesterolemia
Cuevas, A. M., Farias, M. M., & Rodrigo Alonso, K. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000700008

Authors: Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., & Swergold, G. D.
Affiliations: Regeneron (United States) (US)
Medpace (United States) (US)
University of Tennessee Medical Center (US)
IQVIA (United States) (US)
ORCID: Stein, Evan A.
Mellis, Scott
Stahl, Neil
Lisbon, Eleanor
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-03-22
Volume: 366
Issue: 12
Pages: 1108-1118
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1105803
OpenAlex: W1989730880
Semantic Scholar: 04c1ea8c55c4bae0da3106e47141bac81e1bb585
Cited by: 664
References: 15
Citations by year: 2026: 12 · 2025: 11 · 2024: 29 · 2023: 22 · 2022: 19 · 2021: 20 · 2020: 38 · 2019: 29 · 2018: 46 · 2017: 58 · 2016: 62 · 2015: 86 · 2014: 83 · 2013: 92 · 2012: 57
FWCI: 103.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Sanofi
Regeneron Pharmaceuticals
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: PCSK9, monoclonal antibodies, LDL cholesterol, LDL receptor degradation, hypercholesterolemia, familial hypercholesterolemia, atorvastatin, lipid profile, adverse events, dose escalation, cholesterol absorption inhibition
MeSH terms: Atorvastatin, Proprotein Convertase 9, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Hyperlipoproteinemia Type II, Injections, Intravenous, Injections, Subcutaneous, Lipoproteins, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Receptors, LDL, Serine Endopeptidases, Least-Squares Analysis, Proprotein Convertases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks